本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Apellis Pharmaceuticals Inc.

28.17
+0.60002.18%
盘后27.16-1.0100-3.59%19:30 EDT
成交量:192.00万
成交额:5,421.37万
市值:35.58亿
市盈率:-15.44
高:28.60
开:27.54
低:27.14
收:27.57
52周最高:41.94
52周最低:16.10
股本:1.26亿
流通股本:7,811.99万
量比:1.29
换手率:2.46%
股息:- -
股息率:- -
每股收益(TTM):-1.8245
每股收益(LYR):-1.5970
净资产收益率:-108.49%
总资产收益率:-13.77%
市净率:22.76
市盈率(LYR):-17.64

数据加载中...

2024/12/23

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/12/11

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/11/22

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/11/22

超过5%披露

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
2024/11/08

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/11/05

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/09/16

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/09/03

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/08/08

重要事件披露

Form 8-K - Current report
2024/08/01

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/06/21

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/06/05

重要事件披露

Form 8-K - Current report
2024/05/14

重要事件披露

Form 8-K - Current report
2024/05/09

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/05/07

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/04/09

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/04/01

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/20

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities